ABSTRACT
FOXP3 deficiency in mice and in patients with immune dysregulation polyendocrinopathy enteropathy X-linked (IPEX) syndrome results in fatal autoimmunity by altering regulatory T (Treg) cells. CD4+ T cells in patients with IPEX syndrome and Foxp3-deficient mice were analyzed by single-cell cytometry and RNA-sequencing, revealing heterogeneous Treg-like cells, some very similar to normal Treg cells, others more distant. Conventional T cells showed no widespread activation or helper T cell bias, but a monomorphic disease signature affected all CD4+ T cells. This signature proved to be cell extrinsic since it was extinguished in mixed bone marrow chimeric mice and heterozygous mothers of patients with IPEX syndrome. Normal Treg cells exerted dominant suppression, quenching the disease signature and revealing in mutant Treg-like cells a small cluster of genes regulated cell-intrinsically by FOXP3, including key homeostatic regulators. We propose a two-step pathogenesis model: cell-intrinsic downregulation of core FOXP3-dependent genes destabilizes Treg cells, de-repressing systemic mediators that imprint the disease signature on all T cells, furthering Treg cell dysfunction. Accordingly, interleukin-2 treatment improved the Treg-like compartment and survival.
Subject(s)
Diabetes Mellitus, Type 1/congenital , Diarrhea/genetics , Forkhead Transcription Factors/deficiency , Genetic Diseases, X-Linked/genetics , Immune System Diseases/congenital , T-Lymphocytes, Regulatory/immunology , Adolescent , Animals , Case-Control Studies , Child , Child, Preschool , Cohort Studies , Datasets as Topic , Diabetes Mellitus, Type 1/blood , Diabetes Mellitus, Type 1/genetics , Diabetes Mellitus, Type 1/immunology , Diarrhea/blood , Diarrhea/immunology , Disease Models, Animal , Flow Cytometry , Forkhead Transcription Factors/genetics , Genetic Diseases, X-Linked/blood , Genetic Diseases, X-Linked/immunology , Humans , Immune System Diseases/blood , Immune System Diseases/genetics , Immune System Diseases/immunology , Infant , Male , Mice , Mice, Transgenic , Mutation , RNA-Seq , Single-Cell Analysis , T-Lymphocytes, Regulatory/metabolism , Young AdultABSTRACT
BACKGROUND: Late-onset complications in X-linked agammaglobulinemia (XLA) are increasingly recognized. Nodular regenerative hyperplasia (NRH) has been reported in primary immunodeficiency but data in XLA are limited. OBJECTIVES: This study sought to describe NRH prevalence, associated features, and impact in patients with XLA. METHODS: Medical records of all patients with XLA referred to the National Institutes of Health between October 1994 and June 2019 were reviewed. Liver biopsies were performed when clinically indicated. Patients were stratified into NRH+ or NRH- groups, according to their NRH biopsy status. Fisher exact test and Mann-Whitney test were used for statistical comparisons. RESULTS: Records of 21 patients with XLA were reviewed, with a cumulative follow-up of 129 patient-years. Eight patients underwent ≥1 liver biopsy of whom 6 (29% of the National Institutes of Health XLA cohort) were NRH+. The median age at NRH diagnosis was 20 years (range, 17-31). Among patients who had liver biopsies, alkaline phosphatase levels were only increased in patients who were NRH+ (P = .04). Persistently low platelet count (<100,000 per µL for >6 months), mildly to highly elevated hepatic venous pressure gradient and either hepatomegaly and/or splenomegaly were present in all patients who were NRH+. In opposition, persistently low platelet counts were not seen in patients who were NRH-, and hepatosplenomegaly was observed in only 1 patient who was NRH-. Hepatic venous pressure gradient was normal in the only patient tested who was NRH-. All-cause mortality was higher among patients who were NRH+ (5 of 6, 83%) than in the rest of the cohort (1 of 15, 7% among patients who were NRH- and who were classified as unknown; P = .002). CONCLUSIONS: NRH is an underreported, frequent, and severe complication in XLA, which is associated with increased morbidity and mortality.
Subject(s)
Agammaglobulinemia/complications , Genetic Diseases, X-Linked/complications , Hyperplasia/etiology , Adolescent , Adult , Agammaglobulinaemia Tyrosine Kinase/genetics , Agammaglobulinemia/blood , Agammaglobulinemia/genetics , Agammaglobulinemia/pathology , Genetic Diseases, X-Linked/blood , Genetic Diseases, X-Linked/genetics , Genetic Diseases, X-Linked/pathology , Humans , Hyperplasia/blood , Hyperplasia/genetics , Hyperplasia/pathology , Liver/pathology , Male , Mutation , Platelet Count , Retrospective Studies , Young AdultABSTRACT
PURPOSE: This study presents a case of familial transmission of thyroxine-binding globulin (TBG) deficiency. The SERPINA7-gene which codes for TBG is located on the X-chromosome (Xq21-22). More than 45 mutations have been reported to cause TBG- deficiency from various countries, but none from India so far. Genetic analysis of SERPINA7 gene was carried out to determine the cause of low TBG levels in one family. METHODS: DNA samples of the propositus and the family members were subjected to Polymerase Chain Reaction (PCR) followed by direct sequencing. Allele-specific PCR and Next-gen sequencing (NGS) were employed to confirm the site of the mutation. Thyroid function tests were estimated by Radioimmunoassay (RIA) and Immunoradiometric assay (IRMA) kits. X-chromosomal inactivation status was analyzed in the female members harboring the mutation. RESULTS: A mutational screening in this family revealed a novel frame-shift mutation S353Q, 354fs3X in the exon 4 of the SERPINA7 gene which will be referred to as TBG-complete deficiency-India (TBG-CD-Ind). One out of four female family members harboring the mutation showed selective X-chromosomal inactivation. The affected family members were clinically euthyroid initially, showed changes in the thyroid function when tested after a long time span. However, the changes in the thyroid function in the affected family members had an autoimmune etiology. CONCLUSION: This study presents the first report of TBG-CD from India wherein a novel frameshift mutation referred to as TBG-CD-Ind (S353Q, 354fs3X) in the SERPINA7 gene was detected. No apparent association was identified between thyroid function and the TBG-mutation in the affected subjects. A detailed biochemical and genomic testing to determine the exact cause of discordant TFT in the patients would certainly aid in the unequivocal diagnosis of the thyroid function and for the precise individualized treatment.
Subject(s)
Thyroxine-Binding Globulin/analysis , Thyroxine-Binding Globulin/deficiency , Thyroxine-Binding Globulin/genetics , Adult , Female , Genetic Diseases, X-Linked/blood , Genetic Diseases, X-Linked/complications , Genetic Diseases, X-Linked/genetics , Humans , India , Male , Polymerase Chain Reaction/methods , Polymerase Chain Reaction/statistics & numerical data , Thyroid Function Tests/methods , Thyroid Function Tests/statistics & numerical data , Exome Sequencing/methods , Exome Sequencing/statistics & numerical dataABSTRACT
We report three unrelated probands, two male and one female, diagnosed with Aicardi-Goutières syndrome (AGS) after screening positive on California newborn screening (CA NBS) for X-linked adrenoleukodystrophy (X-ALD) due to elevated C26:0 lysophosphatidylcholine (C26:0-LPC). Follow-up evaluation was notable for elevated C26:0, C26:1, and C26:0/C22:0 ratio, and normal red blood cell plasmalogens levels in all three probands. Diagnoses were confirmed by molecular sequencing prior to 12 months of age after clinical evaluation was inconsistent with X-ALD or suggestive of AGS. For at least one proband, the early diagnosis of AGS enabled candidacy for enrollment into a therapeutic clinical trial. This report demonstrates the importance of including AGS on the differential diagnosis for individuals who screen positive for X-ALD, particularly infants with abnormal neurological features, as this age of onset would be highly unusual for X-ALD. While AGS is not included on the Recommended Universal Screening Panel, affected individuals can be identified early through state NBS programs so long as providers are aware of a broader differential that includes AGS. This report is timely, as state NBS algorithms for X-ALD are actively being established, implemented, and refined.
Subject(s)
Adrenoleukodystrophy/blood , Autoimmune Diseases of the Nervous System/blood , Genetic Diseases, X-Linked/blood , Neonatal Screening , Nervous System Malformations/blood , Adrenoleukodystrophy/complications , Adrenoleukodystrophy/genetics , Adrenoleukodystrophy/pathology , Autoimmune Diseases of the Nervous System/complications , Autoimmune Diseases of the Nervous System/genetics , Autoimmune Diseases of the Nervous System/pathology , Dried Blood Spot Testing , Female , Genetic Diseases, X-Linked/complications , Genetic Diseases, X-Linked/genetics , Genetic Diseases, X-Linked/pathology , Humans , Infant , Infant, Newborn , Lysophosphatidylcholines/blood , Male , Nervous System Malformations/complications , Nervous System Malformations/genetics , Nervous System Malformations/pathology , Tandem Mass SpectrometryABSTRACT
INTRODUCTION AND OBJECTIVES: X-linked agammaglobulinemia (XLA), the first known primary immunodeficiency, is caused by rare mutations in Bruton's tyrosine kinase (BTK) gene. Mutations in the BTK gene lead to a failure in the development and maturation of B-cell linage. A decreased number of B-cells results in agammaglobulinemia and increased susceptibility to a variety of infections. Therefore, patients with XLA usually manifest with repetitive bacterial infections, such as upper respiratory tract infections, septic arthritis, osteomyelitis, and urinary tract infections, since their infancy. PATIENTS: We report a 17-year-old Iranian boy with XLA, referred to us with a history of severe and recurrent episodes of bacterial infections for a period of six years. RESULTS: Genetic analysis using the whole Exome sequencing revealed a hemizygous missense mutation in the BTK gene (c.428 A > T, p.His143Leu). CONCLUSION: To our knowledge, c.428 A > T has not been reported in the BTK gene.
Subject(s)
Agammaglobulinaemia Tyrosine Kinase/genetics , Agammaglobulinemia/genetics , Genetic Diseases, X-Linked/genetics , Adolescent , Agammaglobulinemia/blood , Agammaglobulinemia/diagnosis , Agammaglobulinemia/immunology , DNA Mutational Analysis , Genetic Diseases, X-Linked/blood , Genetic Diseases, X-Linked/diagnosis , Genetic Diseases, X-Linked/immunology , Genetic Testing , Humans , Iran , Male , Mutation, Missense , PedigreeABSTRACT
BACKGROUND: Patients with X-linked agammaglobulinemia (XLA) are protected against invasive bacterial infections due to IgG replacement therapy, but are still at higher risk for mucosal infections of the gut and respiratory tract. This might be explained by to the lack of IgA and IgM, as these antibodies are especially important for protection against invading bacterial pathogens on the mucosal surface. METHODS: In an attempt to eliminate a chronic norovirus infection in a patient with X-linked agammaglobulinemia, fresh frozen plasma (FFP) was given two times a week for 3 weeks. At each visit, pre- and post-FFP infusion serum and saliva was collected to determine IgG-, IgA- and IgM-concentrations and serum half-life was calculated. Functionality of the immunoglobulins pre- and post-FFP infusion in both serum and saliva was tested by measuring complement activation, agglutination and killing of non-typeable Haemophilus influenzae (NTHi). RESULTS: Administration of FFP failed to eradicate the chronic norovirus infection. Serum IgA and IgM half-life was 4.2 ± 0.3 and 3.8 ± 0.3 days, respectively. The presence of serum IgM was associated with increased complement binding and complement-mediated killing of NTHi. IgA in saliva was detectable post-FFP and was associated with increased agglutination of NTHi. IgM in saliva was not detectable. CONCLUSIONS: We conclude that FFP treatment, although ineffective in clearing a chronic norovirus infection in this single patient, might be beneficial to prevent or eliminate bacterial infections in XLA patients by increasing IgM dependent complement-mediated killing in serum and IgA dependent bacterial agglutination on the mucosal surface.
Subject(s)
Agammaglobulinemia/blood , Agammaglobulinemia/therapy , Genetic Diseases, X-Linked/blood , Genetic Diseases, X-Linked/therapy , Immunoglobulin A/blood , Immunoglobulin M/blood , Plasma/metabolism , Saliva/metabolism , Agammaglobulinemia/microbiology , Agglutination , Child, Preschool , Complement C3/metabolism , Cytotoxicity, Immunologic , Genetic Diseases, X-Linked/microbiology , Haemophilus influenzae/physiology , Humans , Male , Protein Binding , Young AdultABSTRACT
Nephrogenic syndrome of inappropriate antidiuresis (NSIAD), first described in 2005, is a rare genetic X-linked disease, presenting with hyponatremia, hyposmolarity, euvolemia, inappropriately concentrated urine, increased natriuresis, and undetectable or very low arginine-vasopressine (AVP) circulating levels. It can occur in neonates, infants, or later in life. NSIAD must be early recognized and treated to prevent severe hyponatremia, which can show a dangerous impact on neonatal outcome. In fact, it potentially leads to death or, in case of survival, neurologic sequelae. This review is an update of NSIAD 12 years after the first description, focusing on reported cases of neonatal and infantile onset. The different molecular patterns affecting the AVP receptor 2 (V2R) and determining its gain of function are reported in detail; moreover, we also provide a comparison between the different triggers involved in the development of hyponatremia, the evolution of the symptoms, and modality and efficacy of the different treatments available.
Subject(s)
Genetic Diseases, X-Linked/etiology , Hyponatremia/therapy , Inappropriate ADH Syndrome/etiology , Receptors, Vasopressin/genetics , Renal Reabsorption/genetics , Age of Onset , Antidiuretic Hormone Receptor Antagonists/administration & dosage , Clinical Trials as Topic , Diuretics, Osmotic/administration & dosage , Drinking/physiology , Gain of Function Mutation , Genetic Diseases, X-Linked/blood , Genetic Diseases, X-Linked/diagnosis , Genetic Diseases, X-Linked/therapy , Humans , Hyponatremia/blood , Hyponatremia/etiology , Inappropriate ADH Syndrome/blood , Inappropriate ADH Syndrome/diagnosis , Inappropriate ADH Syndrome/therapy , Infant , Infant, Newborn , Mutation, Missense , Receptors, Vasopressin/metabolism , Signal Transduction/genetics , Sodium/blood , Treatment Outcome , Urea/administration & dosage , Vasopressins/metabolismABSTRACT
OBJECTIVES: To characterise the clinical features, immune manifestations and molecular mechanisms in a recently described autoinflammatory disease caused by mutations in TRNT1, a tRNA processing enzyme, and to explore the use of cytokine inhibitors in suppressing the inflammatory phenotype. METHODS: We studied nine patients with biallelic mutations in TRNT1 and the syndrome of congenital sideroblastic anaemia with immunodeficiency, fevers and developmental delay (SIFD). Genetic studies included whole exome sequencing (WES) and candidate gene screening. Patients' primary cells were used for deep RNA and tRNA sequencing, cytokine profiling, immunophenotyping, immunoblotting and electron microscopy (EM). RESULTS: We identified eight mutations in these nine patients, three of which have not been previously associated with SIFD. Three patients died in early childhood. Inflammatory cytokines, mainly interleukin (IL)-6, interferon gamma (IFN-γ) and IFN-induced cytokines were elevated in the serum, whereas tumour necrosis factor (TNF) and IL-1ß were present in tissue biopsies of patients with active inflammatory disease. Deep tRNA sequencing of patients' fibroblasts showed significant deficiency of mature cytosolic tRNAs. EM of bone marrow and skin biopsy samples revealed striking abnormalities across all cell types and a mix of necrotic and normal-appearing cells. By immunoprecipitation, we found evidence for dysregulation in protein clearance pathways. In 4/4 patients, treatment with a TNF inhibitor suppressed inflammation, reduced the need for blood transfusions and improved growth. CONCLUSIONS: Mutations of TRNT1 lead to a severe and often fatal syndrome, linking protein homeostasis and autoinflammation. Molecular diagnosis in early life will be crucial for initiating anti-TNF therapy, which might prevent some of the severe disease consequences.
Subject(s)
Anemia, Sideroblastic/genetics , Anti-Inflammatory Agents/therapeutic use , Genetic Diseases, X-Linked/genetics , Immunologic Deficiency Syndromes/genetics , Mutation , Nucleotidyltransferases/genetics , RNA, Transfer/genetics , Tumor Necrosis Factor-alpha/antagonists & inhibitors , Adult , Anemia, Sideroblastic/blood , Child , Child, Preschool , Cytokines/blood , Cytokines/genetics , Developmental Disabilities/genetics , Female , Genetic Diseases, X-Linked/blood , Humans , Immunophenotyping , Male , Pedigree , Phenotype , Tumor Necrosis Factor-alpha/analysis , Exome SequencingABSTRACT
BACKGROUND: Prenatal diagnosis in pregnancies at risk of single-gene disorders is currently performed using invasive methods such as chorionic villus sampling and amniocentesis. This is in contrast with screening for common aneuploidies, for which noninvasive methods with a single maternal blood sample have become standard clinical practice. METHODS: We developed a protocol for noninvasive prenatal diagnosis of inherited single-gene disorders using droplet digital PCR from circulating cell-free DNA (cfDNA) in maternal plasma. First, the amount of cfDNA and fetal fraction is determined using a panel of TaqMan assays targeting high-variability single-nucleotide polymorphisms. Second, the ratio of healthy and diseased alleles in maternal plasma is quantified using TaqMan assays targeting the mutations carried by the parents. Two validation approaches of the mutation assay are presented. RESULTS: We collected blood samples from 9 pregnancies at risk for different single-gene disorders, including common conditions and rare metabolic disorders. We measured cases at risk of hemophilia, ornithine transcarbamylase deficiency, cystic fibrosis, ß-thalassemia, mevalonate kinase deficiency, acetylcholine receptor deficiency, and DFNB1 nonsyndromic hearing loss. We correctly differentiated affected and unaffected pregnancies (2 affected, 7 unaffected), confirmed by neonatal testing. We successfully measured an affected pregnancy as early as week 11 and with a fetal fraction as low as 3.7% (0.3). CONCLUSIONS: Our method detects single-nucleotide mutations of autosomal recessive diseases as early as the first trimester of pregnancy. This is of importance for metabolic disorders in which early diagnosis can affect management of the disease and reduce complications and anxiety related to invasive testing.
Subject(s)
Genetic Diseases, Inborn/diagnosis , Polymerase Chain Reaction/methods , Prenatal Diagnosis/methods , Adult , Alleles , Cell-Free Nucleic Acids/blood , Clinical Protocols , Female , Fetus/metabolism , Genes, Recessive , Genetic Diseases, Inborn/blood , Genetic Diseases, Inborn/genetics , Genetic Diseases, X-Linked/blood , Genetic Diseases, X-Linked/diagnosis , Genetic Diseases, X-Linked/genetics , Heterozygote , Humans , Mutation , Polymorphism, Single Nucleotide , Pregnancy , Reproducibility of ResultsABSTRACT
Ibrutinib and acalabrutinib are irreversible inhibitors of Bruton tyrosine kinase used in the treatment of B-cell malignancies. They bind irreversibly to cysteine 481 of Bruton tyrosine kinase, blocking autophosphorylation on tyrosine 223 and phosphorylation of downstream substrates including phospholipase C-γ2. In the present study, we demonstrate that concentrations of ibrutinib and acalabrutinib that block Bruton tyrosine kinase activity, as shown by loss of phosphorylation at tyrosine 223 and phospholipase C-γ2, delay but do not block aggregation in response to a maximally-effective concentration of collagen-related peptide or collagen. In contrast, 10- to 20-fold higher concentrations of ibrutinib or acalabrutinib block platelet aggregation in response to glycoprotein VI agonists. Ex vivo studies on patients treated with ibrutinib, but not acalabrutinib, showed a reduction of platelet aggregation in response to collagen-related peptide indicating that the clinical dose of ibrutinib but not acalabrutinib is supramaximal for Bruton tyrosine kinase blockade. Unexpectedly, low concentrations of ibrutinib inhibited aggregation in response to collagen-related peptide in patients deficient in Bruton tyrosine kinase. The increased bleeding seen with ibrutinib over acalabrutinib is due to off-target actions of ibrutinib that occur because of unfavorable pharmacodynamics.
Subject(s)
Agammaglobulinaemia Tyrosine Kinase/antagonists & inhibitors , Agammaglobulinemia/drug therapy , Blood Platelets/drug effects , Genetic Diseases, X-Linked/drug therapy , Platelet Membrane Glycoproteins/metabolism , Protein Kinase Inhibitors/therapeutic use , Adenine/analogs & derivatives , Agammaglobulinaemia Tyrosine Kinase/genetics , Agammaglobulinaemia Tyrosine Kinase/metabolism , Agammaglobulinemia/blood , Agammaglobulinemia/genetics , Benzamides/administration & dosage , Benzamides/metabolism , Blood Platelets/metabolism , Carrier Proteins/administration & dosage , Genetic Diseases, X-Linked/blood , Genetic Diseases, X-Linked/genetics , Humans , Mutation , Peptides/administration & dosage , Piperidines , Platelet Activation/drug effects , Platelet Function Tests , Platelet Membrane Glycoproteins/agonists , Protein Kinase Inhibitors/metabolism , Pyrazines/administration & dosage , Pyrazines/metabolism , Pyrazoles/administration & dosage , Pyrazoles/metabolism , Pyrimidines/administration & dosage , Pyrimidines/metabolismABSTRACT
BACKGROUND: X-linked thrombocytopenia (XLT) is a milder form of Wiskott-Aldrich syndrome (WAS), characterized predominantly by thrombocytopenia with small-sized platelets. Mutations in the WAS gene are responsible for the disease. We herein detected a new mutation in the WAS gene responsible for XLT in a 3-generation Chinese pedigree. METHODS: Peripheral blood samples were collected from 7 members in the family. WAS gene was amplified from genomic DNA isolated from leucocytes, and then direct sequencing was performed. RESULTS: Three male members of this family (the proband, his younger brother and maternal uncle) had thrombocytopenia and decreased mean platelet volume. A homozygous mutation (T>C) was found at nucleotide position 319 in exon 3, causing the amino acid Tyr (T) to be abnormally changed to His (H) at position 107. Two female members (the proband's mother and grandmother) were carriers of the mutation. CONCLUSIONS: XLT is easy to misdiagnose as immune thrombocytopenic purpura (ITP). The diagnosis of XLT should be considered in any male with congenital microthrombocytopenia or early onset of microthrombocytope-nia (< 7 fL). This article adds to the growing number of known mutations associated with XLT.
Subject(s)
Genetic Diseases, X-Linked/genetics , Mutation, Missense , Thrombocytopenia/genetics , Wiskott-Aldrich Syndrome Protein/genetics , Wiskott-Aldrich Syndrome/genetics , Adolescent , Asian People/genetics , Base Sequence , China , DNA Mutational Analysis , Exons/genetics , Female , Genetic Diseases, X-Linked/blood , Genetic Diseases, X-Linked/ethnology , Humans , Male , Mean Platelet Volume , Pedigree , Thrombocytopenia/blood , Thrombocytopenia/ethnology , Wiskott-Aldrich Syndrome/blood , Wiskott-Aldrich Syndrome/ethnologyABSTRACT
Patients with primary antibody deficiency (PAD) are being increasingly diagnosed in the developing world. However, care of these children continues to remain suboptimal due to financial and social constraints. Immunoglobulin (Ig) trough level is an important predicting factor for infections in children on replacement immunoglobulin therapy. There are no data on this aspect from the developing world. Therefore, we studied serial immunoglobulin G (IgG) trough levels in 14 children with X-linked agammaglobulinemia (XLA) receiving replacement intravenous immunoglobulin (IVIG). Infections during the course of enrolment were documented prospectively. Mean age at the time of diagnosis was 5.1 years (range 2-11 years). Mean time from onset of symptoms and initiation of therapy was 3.3 years. Two children had established chronic lung disease prior to enrolment. Total numbers of major and minor infections were 7 and 40, respectively. At a mean dose of 414 mg/kg/month of IVIG, mean trough IgG level was 435 mg/dl. Median IgG trough levels during the episodes of major and minor infections were 244 and 335 mg/dl, respectively. An escalation in IVIG dose of 100 mg/kg produced an increase in serum IgG levels by 53.6 mg/dl. Median trough IgG level of 354 mg/dl was found to be protective with 64% sensitivity and 75% specificity. A median dose of 397 mg/kg was required to keep children free of infections. Despite financial constraints and several challenges in the context of a developing country, children with XLA have good outcome on replacement immunoglobulin therapy. Furthermore, mean biological trough IgG levels are much lower than reported in for Western patients; however, studies involving larger number of subjects are required in future to draw firm conclusions.
Subject(s)
Agammaglobulinemia/blood , Agammaglobulinemia/drug therapy , Genetic Diseases, X-Linked/blood , Genetic Diseases, X-Linked/drug therapy , Immunoglobulin G/blood , Immunoglobulins, Intravenous/therapeutic use , Adolescent , Agammaglobulinemia/complications , Agammaglobulinemia/diagnosis , Child , Child, Preschool , Female , Follow-Up Studies , Genetic Diseases, X-Linked/complications , Genetic Diseases, X-Linked/diagnosis , Humans , Immunoglobulin Isotypes/blood , India , Infections/etiology , Male , Phenotype , ROC Curve , Treatment Outcome , Young AdultABSTRACT
Mutations in the C-terminus of human erythroid 5-aminolevulinate synthase (hALAS2), a pyridoxal 5'-phosphate (PLP)-dependent enzyme, are associated with two different blood disorders, X-linked sideroblastic anemia (XLSA) and X-linked protoporphyria (XLPP). XLSA-causing mutations yield hALAS2 variants with decreased activity, while XLPP-causing mutations result in a gain-of-function of hALAS2. There are no specific treatments for XLPP. Isonicotinic acid hydrazide (isoniazid, INH), an antituberculosis agent, can cause sideroblastic anemia as a side-effect, by limiting PLP availability to hALAS2, via inhibition of pyridoxal kinase or reaction with pyridoxal to form pyridoxal isonicotinoyl hydrazone. We hypothesized that INH also binds and directly inhibits hALAS2. Using fluorescence-activated cell sorting and confocal fluorescence microscopy, we demonstrate that INH reduces protoporphyrin IX levels in HeLa cells expressing either wild-type hALAS2 or XLPP variants. In addition, PLP and pyridoxamine 5'-phosphate (PMP) reversed the cellular inhibition of hALAS2 activity by INH. Steady-state kinetic analyses with purified hALAS2 indicated that INH directly inhibits the enzyme, noncompetitively or uncompetitively, with an apparent Ki of 1.2µM. Circular dichroism spectroscopy revealed that INH triggered tertiary structural changes in hALAS2 that altered the microenvironment of the PLP cofactor and hampered the association of PLP with apo-hALAS2. Treatment of four XLPP patients with INH (5mg·kg-1·day-1) over a six-month period was well tolerated but without statistically significant modification of PPIX levels. These results, taken together, permit us to further an INH inhibition kinetic mechanism for ALAS, which suggests the possible use of INH-derived drugs in treating patients with XLPP and potentially other protoporphyrin-accumulating porphyrias.
Subject(s)
5-Aminolevulinate Synthetase/deficiency , Enzyme Inhibitors/pharmacology , Genetic Diseases, X-Linked/drug therapy , Isoniazid/pharmacology , Protoporphyria, Erythropoietic/drug therapy , 5-Aminolevulinate Synthetase/antagonists & inhibitors , 5-Aminolevulinate Synthetase/blood , 5-Aminolevulinate Synthetase/chemistry , 5-Aminolevulinate Synthetase/metabolism , Anemia, Sideroblastic/enzymology , Enzyme Inhibitors/therapeutic use , Genetic Diseases, X-Linked/blood , Genetic Diseases, X-Linked/enzymology , HeLa Cells , Humans , Isoniazid/therapeutic use , Protein Binding/drug effects , Protein Structure, Tertiary/drug effects , Protoporphyria, Erythropoietic/blood , Protoporphyria, Erythropoietic/enzymology , Protoporphyrins/blood , Pyridoxal Phosphate/metabolism , Pyridoxine/pharmacology , Vitamin B Complex/pharmacologyABSTRACT
BACKGROUND: Researchers have developed approaches for the noninvasive prenatal testing of single gene diseases. One approach that allows for the noninvasive assessment of both maternally and paternally inherited mutations involves the analysis of single nucleotide polymorphisms (SNPs) in maternal plasma DNA with reference to parental haplotype information. In the past, parental haplotypes were resolved by complex experimental methods or inferential approaches, such as through the analysis of DNA from other affected family members. Recently, microfluidics-based linked-read sequencing technology has become available and allows the direct haplotype phasing of the whole genome rapidly. We explored the feasibility of applying this direct haplotyping technology in noninvasive prenatal testing. METHODS: We first resolved the haplotypes of parental genomes with the use of linked-read sequencing technology. Then, we identified SNPs within and flanking the genes of interest in maternal plasma DNA by targeted sequencing. Finally, we applied relative haplotype dosage analysis to deduce the mutation inheritance status of the fetus. RESULTS: Haplotype phasing and relative haplotype dosage analysis of 12 out of 13 families were successfully achieved. The mutational status of these 12 fetuses was correctly classified. CONCLUSIONS: High-throughput linked-read sequencing followed by maternal plasma-based relative haplotype dosage analysis represents a streamlined approach for noninvasive prenatal testing of inherited single gene diseases. The approach bypasses the need for mutation-specific assays and is not dependent on the availability of DNA from other affected family members. Thus, the approach is universally applicable to pregnancies at risk for the inheritance of a single gene disease.
Subject(s)
DNA/genetics , Genetic Diseases, Inborn/genetics , Genetic Diseases, X-Linked/genetics , Haplotypes/genetics , Polymorphism, Single Nucleotide/genetics , Prenatal Diagnosis , Sequence Analysis, DNA , DNA/blood , Female , Genetic Diseases, Inborn/blood , Genetic Diseases, X-Linked/blood , Humans , Male , Microfluidic Analytical Techniques , Mutation , PregnancyABSTRACT
UNLABELLED: Because Wiskott-Aldrich syndrome (WAS) and X-linked thrombocytopenia (XLT) patients have microthrombocytopenia, hemorrhage is a major problem. We asked whether eltrombopag, a thrombopoietic agent, would increase platelet counts, improve platelet activation, and/or reduce bleeding in WAS/XLT patients. In 9 WAS/XLT patients and 8 age-matched healthy controls, platelet activation was assessed by whole blood flow cytometry. Agonist-induced platelet surface activated glycoprotein (GP) IIb-IIIa and P-selectin in WAS/XLT patients were proportional to platelet size and therefore decreased compared with controls. In contrast, annexin V binding showed no differences between WAS/XLT and controls. Eltrombopag treatment resulted in an increased platelet count in 5 out of 8 patients. Among responders to eltrombopag, immature platelet fraction in 3 WAS/XLT patients was significantly less increased compared with 7 pediatric chronic immune thrombocytopenia (ITP) patients. Platelet activation did not improve in 3 WAS/XLT patients whose platelet count improved on eltrombopag. IN CONCLUSION: (1) the reduced platelet activation observed in WAS/XLT is primarily due to the microthrombocytopenia; and (2) although the eltrombopag-induced increase in platelet production in WAS/XLT is less than in ITP, eltrombopag has beneficial effects on platelet count but not platelet activation in the majority of WAS/XLT patients. This trial was registered at www.clinicaltrials.gov as #NCT00909363.
Subject(s)
Benzoates/therapeutic use , Genetic Diseases, X-Linked/blood , Genetic Diseases, X-Linked/drug therapy , Hydrazines/therapeutic use , Pyrazoles/therapeutic use , Thrombocytopenia/blood , Thrombocytopenia/drug therapy , Wiskott-Aldrich Syndrome/blood , Wiskott-Aldrich Syndrome/drug therapy , Adolescent , Adult , Case-Control Studies , Child , Child, Preschool , Humans , Infant , Male , Mean Platelet Volume , P-Selectin/blood , Platelet Activation/drug effects , Platelet Count , Platelet Glycoprotein GPIIb-IIIa Complex/metabolism , Receptors, Thrombopoietin/agonists , Young AdultABSTRACT
Patients affected by protocadherin 19 (PCDH19)-female limited epilepsy (PCDH19-FE) present a remarkable reduction in allopregnanolone blood levels. However, no information is available on other neuroactive steroids and the steroidogenic response to hormonal stimulation. For this reason, we evaluated allopregnanolone, pregnanolone, and pregnenolone sulfate by liquid chromatographic procedures coupled with electrospray tandem mass spectrometry in 12 unrelated patients and 15 age-matched controls. We also tested cortisol, estradiol, progesterone, and 17OH-progesterone using standard immunoassays. Apart from estradiol and progesterone, all the considered hormones were evaluated in basal condition and after stimulation with adrenocorticotropic hormone (ACTH). A generalized decrease in blood levels of almost all measured neuroactive steroids was found. When considering sexual development, cortisol and pregnenolone sulfate basal levels were significantly reduced in postpubertal girls affected by PCDH19-FE. Of interest, ACTH administration did not recover pregnenolone sulfate serum levels but restored cortisol to control levels. In prepubertal girls with PCDH19-FE, by challenging adrenal function with ACTH we disclosed defects in the production of cortisol, pregnenolone sulfate, and 17OH-progesterone, which were not apparent in basal condition. These findings point to multiple defects in peripheral steroidogenesis associated with and potentially relevant to PCDH19-FE. Some of these defects could be addressed by stimulating adrenocortical activity.
Subject(s)
Cadherins/genetics , Epilepsy/blood , Epilepsy/genetics , Genetic Diseases, X-Linked/blood , Genetic Diseases, X-Linked/genetics , Gonadal Steroid Hormones/blood , Intellectual Disability/blood , Intellectual Disability/genetics , Pregnanolone/blood , Pregnanolone/deficiency , Pregnenolone/blood , 17-alpha-Hydroxyprogesterone/blood , Adolescent , Adrenocorticotropic Hormone/pharmacology , Adrenogenital Syndrome/blood , Case-Control Studies , Child , Child, Preschool , DNA Mutational Analysis , Estradiol/blood , Female , Humans , Hydrocortisone/blood , Progesterone/blood , Prospective Studies , Protocadherins , Puberty, Precocious/blood , Puberty, Precocious/genetics , Reference ValuesABSTRACT
BACKGROUND: Thrombocytopenia can occur in different circumstances during childhood and although immune thrombocytopenia is its most frequent cause, it is important to consider other conditions, especially when there is a persistent or recurrent low platelet count. We report two cases of intermittent thrombocytopenia, previously misdiagnosed as immune thrombocytopenia. CASES PRESENTATION: Both cases described were boys who presented with an intermittent pattern of thrombocytopenia, with a persistently low mean platelet volume. In both patients, peripheral blood smear revealed small platelets and flow cytometry showed low expression of Wiskott-Aldrich syndrome protein (WASP) in leucocytes. Molecular analysis of the first case identified a mutation in exon 2 of the gene coding for WASP, leading to a p.Thr45Met amino acid change and confirming the diagnosis of X-linked thrombocytopenia. In the second case, a novel missense mutation in exon 2 of the gene coding for WASP was detected, which resulted in a p.Pro58Leu amino acid change. CONCLUSION: These two rare presentations of thrombocytopenia highlight the importance of evaluating the peripheral blood smear in the presence of recurrent or persistent thrombocytopenia and show that failing to do so can lead to misdiagnoses. Since thrombocytopenia may be found in pediatric outpatient clinic, increased awareness among general pediatricians will help to improve the differential diagnosis of this condition.
Subject(s)
Genetic Diseases, X-Linked/diagnosis , Thrombocytopenia/diagnosis , Wiskott-Aldrich Syndrome Protein/genetics , Child, Preschool , Diagnostic Errors , Genetic Diseases, X-Linked/blood , Genetic Diseases, X-Linked/genetics , Genetic Markers , Humans , Infant , Male , Mutation , Platelet Count , Thrombocytopenia/blood , Thrombocytopenia/geneticsABSTRACT
Dent disease classically combines low-molecular-weight proteinuria, hypercalciuria with nephrocalcinosis, and renal failure. Nephrotic range proteinuria, normal calciuria, and hypokalemia have been rarely reported. It is unknown whether the changes in phenotype observed over time are explained by a decrease in glomerular filtration rate (GFR) or whether there is any phenotype-genotype relationship. To answer this we retrospectively analyzed data from 109 male patients with CLCN5 mutations (Dent-1) and 9 patients with mutation of the OCRL gene (Dent-2). In Dent-1 disease, the estimated GFR decreased with age, by 1.0 to 1.6 ml/min per 1.73 m(2)/yr in the absence and presence of nephrocalcinosis, respectively, with no significant difference. Median values of low-molecular-weight proteinuria were in the nephrotic range and remained at the same level even in late renal disease. End-stage renal disease occurred in 12 patients, at a median age of 40 years. Hypercalciuria decreased with glomerular filtration and was absent in 40% of the patients under 30 and 85% of those over the age of 30. Hypophosphatemia did not resolve with age and calcitriol concentrations were in the upper normal range. Kalemia decreased with age, with half of the patients over the age of 18 presenting with hypokalemia. Thus, no phenotype/genotype correlation was observed in this cohort of patients with Dent disease.
Subject(s)
Chloride Channels/genetics , Genetic Diseases, X-Linked/genetics , Kidney Failure, Chronic/epidemiology , Nephrolithiasis/genetics , Phosphoric Monoester Hydrolases/genetics , Adolescent , Adult , Age Factors , Child , Child, Preschool , Genetic Association Studies , Genetic Diseases, X-Linked/blood , Genetic Diseases, X-Linked/complications , Genetic Diseases, X-Linked/urine , Genotype , Glomerular Filtration Rate , Humans , Hypercalciuria/genetics , Hypercalciuria/urine , Hypophosphatemia/blood , Hypophosphatemia/genetics , Kidney Failure, Chronic/etiology , Male , Middle Aged , Mutation , Nephrolithiasis/blood , Nephrolithiasis/complications , Nephrolithiasis/urine , Phenotype , Proteinuria/genetics , Proteinuria/urine , Retrospective Studies , Young AdultSubject(s)
Autoantibodies/blood , Diabetes Mellitus, Type 1/congenital , Diarrhea/blood , Genetic Diseases, X-Linked/blood , Immune System Diseases/congenital , Isaacs Syndrome/blood , Potassium Channels, Voltage-Gated/immunology , Adolescent , Child , Diabetes Mellitus, Type 1/blood , Diabetes Mellitus, Type 1/genetics , Diabetes Mellitus, Type 1/immunology , Diabetes Mellitus, Type 1/therapy , Diarrhea/genetics , Diarrhea/immunology , Diarrhea/therapy , Forkhead Transcription Factors/genetics , Genetic Diseases, X-Linked/genetics , Genetic Diseases, X-Linked/immunology , Genetic Diseases, X-Linked/therapy , Hematopoietic Stem Cell Transplantation , Humans , Immune System Diseases/blood , Immune System Diseases/genetics , Immune System Diseases/immunology , Immune System Diseases/therapy , Infant, Newborn , Isaacs Syndrome/genetics , Isaacs Syndrome/immunology , Isaacs Syndrome/therapy , Male , MutationABSTRACT
BACKGROUND: X-linked agammaglobulinemia (XLA) is an X-linked genetic defect in maturation of B lymphocytes that results in the absence of B lymphocytes in the peripheral blood and profound hypogammaglobulinemia. It is caused by a mutation in the BTK gene located on the X chromosome. There are no large series describing XLA from the developing world. OBJECTIVE: To analyze the clinical features, immunologic and genetic characteristics, and outcomes of 36 patients with XLA diagnosed and managed for a period of 2 decades. METHODS: Diagnosis of XLA was made on the basis of presence of BTK gene mutation or marked reduction of B lymphocytes in peripheral blood with a family history of an affected male relative. The diagnosis was confirmed by genetic mutation studies in 28 patients with 25 unique mutations in the BTK gene. RESULTS: There was a significant delay in diagnosis in most of the patients. The mean (SD) delay in the diagnosis was 4.2 (3.5) years. Point mutations were the most common mutations detected, accounting for 68% of all mutations. Deletions and insertions were also seen in a few cases. Four of the mutations are novel mutations that have not been previously reported. Seven of the 36 patients (19%) were dead at the time of analysis in the present cohort. The mean survival was 137 months (95% confidence interval, 13-163 months). CONCLUSION: The present study is perhaps the largest series of patients with XLA from any developing country so far.